Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949491 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL15459906 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7111379 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL13646020 | 0.91 | PNP (0.63) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7742864 | 0.91 | PNP (0.63) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23982120 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL1678967 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL176347 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL21562191 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL8712178 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232387-B2 | Process for the preparation of cladribine | SCINOPHARM TAIWAN, LTD. (TW) | 2012-07-31 | — | — | US | disclosed |
| US-20110046363-A1 | Process for the Preparation of Cladribine | SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) | 2011-02-24 | — | — | US | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1042348-A4 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1042348-A1 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031119-A1 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | PNP 14/4885LMNA 3214/4885TP53 2160/4885 |
| US-20110046363-A1 | Process for the Preparation of Cladribine | ADAR, RNMT, RNGTT | PNP 7/4885LMNA 2058/4885TP53 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.